Catalio Capital Management, LP has filed its 13F form on February 14, 2025 for Q4 2024 where it was disclosed a total value porftolio of $457 Billion distributed in 33 stocks.

Among their holdings, we can observe that their the top five positions include companies like: Becton Dickinson & CO with a value of $33.7B, Ascendis Pharma A/S with a value of $29.7B, Bristol Myers Squibb CO with a value of $28.2B, Spring Works Therapeutics, Inc. with a value of $27.6B, and Blueprint Medicines Corp with a value of $24.8B.

Examining the 13F form we can see an increase of $457B in the current position value.

Catalio Capital Management, LP is based out at New York, NY

Below you can find more details about Catalio Capital Management, LP portfolio as well as his latest detailed transactions.

Portfolio value $457 Billion
Healthcare: $384 Billion

Stock Holdings Table Market Cap. of $50 Millions to $300 Millions

Stock Market Cap. Holding Value (Reported) # of Shares. Last Trade Trade History

Summary

  • Portfolio
  • No. of Stocks 33
  • Current Value $457 Billion
  • Filing
  • Period Q4 2024
  • Filing Date February 14, 2025
  • Form Type 13F-HR
  • Activity in Q4 2024
  • New Purchases 33 stocks
  • Additional Purchases 0 stocks
  • Sold out of 0 stocks
  • Reduced holdings in 0 stocks
Track This Portfolio

Track Catalio Capital Management, LP Portfolio

Follow Catalio Capital Management, LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Catalio Capital Management, LP, based on Form 13F filings with the SEC.

News

Stay updated on Catalio Capital Management, LP with notifications on news.